ClinicalTrials.gg
CompletedNCT05715528OAKTREEUpdated Dec 24, 2024Results posted

Study of Obeldesivir in Nonhospitalized Participants With COVID-19

A Phase 3 interventional study of Obeldesivir and Obeldesivir Placebo in COVID-19, sponsored by Gilead Sciences. Completed at 113 sites in 2 countries. Open to participants aged 12 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-12-24.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,011
Allocation
Randomized
Ages
12 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in COVID-19 by Gilead Sciences — none open to participants now, none under way, none of them phase 3. COVID-19 · Gilead Sciences.

Started
2023
with 1 other
Phase 3
6 of 10
none open now
Registered
9th of 10
by date

Among the 10 studies in COVID-19 by Gilead Sciences, this one is one of 2 that started in 2023, is one of 6 in phase 3, and was the 9th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 10 studies in COVID-19 by Gilead Sciences is open now. The open studies under COVID-19, anywhere →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 12 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in COVID-19 by Gilead Sciences as a file.
02

Study summary

The goal of this clinical study is to test if obeldesivir (GS-5245) is safe and effective for the treatment of coronavirus disease 2019 (COVID-19) in participants who have a standard risk of developing severe illness. This study will also measure how much obeldesivir gets into the blood and how long it takes for the body to get rid of it.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
12 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection confirmed, ≤ 3 days before randomization, by polymerase chain reaction (PCR), rapid antigen test, or an approved alternative assay. Serologic tests will not be accepted.
  • Willing and able to complete the coronavirus disease 19 (COVID-19) symptom questionnaire prior to first dose and daily throughout the study period.
  • Initial onset of COVID-19 signs/symptoms ≤ 3 days before randomization with ≥ 2 of the following targeted symptoms, at moderate or higher severity, present at randomization.

    • Stuffy or runny nose.
    • Sore throat.
    • Shortness of breath (difficulty breathing).
    • Cough.
    • Low energy or tiredness.
    • Muscle or body aches.
    • Headache.
    • Chills or shivering.
    • Feeling hot or feverish.
  • Not currently hospitalized or requiring hospitalization.

Key Exclusion Criteria:

  • Any risk factors for progression to severe disease.
  • Planning to receive a direct acting antiviral or monoclonal antibody against SARS-CoV-2 for the treatment of COVID-19.
  • Received any direct acting antiviral drug or monoclonal antibody against SARS-CoV-2 for the treatment of COVID-19 \< 28 days or \< 5 half-lives, whichever is longer, before randomization.
  • Received any convalescent COVID-19 plasma or other antibody-based anti-SARS-CoV-2 prophylaxis at any time prior to study entry.
  • Received an COVID-19 vaccine (including booster dose) \< 120 days before randomization.
  • Self-reported COVID-19 diagnosis \< 120 days before randomization.
  • Anticipated need for hospitalization \< 48 hours after randomization.
  • New oxygen requirement \< 24 hours before randomization.
  • Known influenza, or any other suspected or confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the study drug.
  • Known history of chronic liver disease, limited to cirrhosis, nonalcoholic steatohepatitis, alcoholic liver disease, and hepatitis.
  • Undergoing dialysis, or known history of chronic kidney disease.
  • Persistent symptoms from previous COVID-19 illness that may interfere with the evaluation of response to the study drug.
  • Pregnant or breastfeeding.
  • Unwilling to use protocol-mandated .
  • Any other factor, including inability to complete the patient-reported outcome (PRO) questionnaire for the primary endpoint, making the individual, in the opinion of the investigator, unsuitable to participate in the study.
  • Concurrent participation/enrollment in a separate therapeutic clinical study.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,011 participants (actual)

Study arms

  • Experimental
    Obeldesivir

    Participants will receive obeldesivir 350 mg twice daily for 5 days.

    Drug: Obeldesivir

  • Placebo comparator
    Obeldesivir Placebo

    Participants will receive obeldesivir placebo twice daily for 5 days.

    Drug: Obeldesivir Placebo

Interventions

  • Tablet administered orally without regard to food.

    Also known as: GS-5245

  • DrugObeldesivir Placebo

    Tablet administered orally without regard to food.

06

What researchers measure

Primary outcomes

  1. Time to Coronavirus Disease 2019 (COVID-19) Symptom Alleviation by Day 29

    The time to alleviation of targeted COVID-19 symptoms by Day 29 for participants with symptom alleviation, was calculated as symptom alleviation date/time minus first dose date/time. For participants who completed Day 29 of the study or discontinued from the study before Day 29 without symptom alleviation (censored) and without inter-current events, time was calculated as last date/time on which symptom alleviation was assessed minus the first dose date/time or Day 28, whichever occurred first. Symptom alleviation was defined as, all targeted symptoms scored moderate or severe at baseline were scored as mild/none and all targeted symptoms scored mild/none at baseline were scored as none, for at least 48 consecutive hours. Targeted symptoms included: stuffy or runny nose, sore throat, shortness of breath, cough, low energy or tiredness, muscle or body aches, headache, chills or shivering and feeling hot or feverish. Kaplan-Meier (KM) estimates were used in outcome measure analysis.

    Time frame: First dose date up to Day 29

  2. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    TEAEs were defined as 1 or both of the following: * Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug. * Any AEs leading to premature discontinuation of study drug. Percentages were rounded off.

    Time frame: First dose date up to Day 5 plus 30 days

  3. Percentage of Participants Experiencing Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days. Percentages were rounded off.

    Time frame: First dose date up to Day 5 plus 30 days

  4. Percentage of Participants Experiencing Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation

    Percentages were rounded off.

    Time frame: First dose date up to Day 5 plus 30 days

Secondary outcomes

  1. Time to COVID-19 Symptom Resolution by Day 29

    COVID-19 symptom resolution was defined as all targeted symptoms scored as none for at least 48 consecutive hours. The first day of the 48 consecutive hours was considered the date of symptom resolution. The time to COVID-19 symptom resolution was the time (expressed as days) from the first dose date/time to the date/time of symptom resolution. KM estimates were used in the outcome measure analysis.

    Time frame: Day 1 up to 29

  2. Percentage of Participants With Moderate Relapse of COVID-19 Symptoms by Day 29

    COVID-19 moderate symptom relapse was defined as having at least 1 symptom being moderate or severe OR at least 2 mild symptoms OR a hospitalization for COVID-19 or death, observed on a day during COVID-19 symptom relapse. Percentages were rounded off.

    Time frame: Up to Day 29

  3. Percentage of Participants With COVID-19 Related Medically Attended Visits (MAVs) or All-cause Death by Day 29

    Medically attended visits were defined as interactions with health care professionals other than study staff or designees including hospitalization; in-person emergency, urgent, or primary care visits; or any other in-person visit attended by the participant and a health care professional. The nature and cause of the visit were identified. KM estimates were used in the outcome measure analysis. Percentages were rounded off.

    Time frame: Up to Day 29

  4. Percentage of Participants With COVID-19 Related Hospitalization or All-cause Death by Day 29

    COVID-19-related hospitalization was defined as ≥ 24 hours of acute care for a reason related to COVID-19, in a hospital or similar acute care facility, including emergency rooms or temporary facilities instituted to address medical needs of those with COVID-19. This included specialized acute medical care units within an assisted living facility or nursing home. This did not include hospitalization for the purposes of public health and/or clinical trial execution. The date and duration (if there was 1 day difference between the start date and end date) of hospital admission, and primary reason for hospitalization (including if the hospitalization was related to COVID-19) was to be recorded. Percentages were rounded off.

    Time frame: Up to Day 29

  5. Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nasal Swab Viral Load at Day 5

    Time frame: Day 5

  6. Time to Antigen Negativity

    Time to antigen negativity was defined (in days) as the number of days to the first date of 2 consecutive dates achieving a negative result. Antigen negativity was defined as 2 consecutive negative SARS-CoV-2 rapid antigen test (regardless if there was missing data in between), or negative test at last available sample for participants who completed or discontinued from the study after at least 1 positive antigen test.

    Time frame: Day 1 up to Day 29

  7. Percentage of Participants With Viral Antigen Rebound

    Viral antigen rebound was defined as any positive SARS-CoV-2 rapid antigen test after antigen negativity. Percentages were rounded off.

    Time frame: Up to Day 29

  8. Plasma Concentrations of GS-441524 (Metabolite of Obeldesivir)

    Time frame: Day 1, 0.75 hour and 2 hours; Day 3, Predose and 0.75 hour; Day 5, Predose and 0.75 hour

  9. Pharmacokinetic (PK) Parameter: AUCtau,Steady-State of GS-441524

    AUCtau is defined as the area under the concentration versus time curve over the dosing interval at steady-state.

    Time frame: Day 5

  10. PK Parameter: Ctau of GS-441524

    Ctau is defined as the observed drug concentration at the end of the dosing interval.

    Time frame: Day 1 and Day 5

  11. PK Parameter: Cmax of GS-441524

    Cmax is defined as the maximum observed plasma concentration of drug.

    Time frame: Day 1 and Day 5

  12. Percentage of Participants With Relapse of COVID-19 Symptoms by Day 29

    Symptom relapse means at least 2 consecutive diary entries (regardless of missing data in between) where there was any symptom (regardless of severity) OR a hospitalization for COVID-19 or a death after short symptom recovery. Percentages were rounded off.

    Time frame: Up to Day 29

07

Results

Posted Dec 24, 2024

Participant flow

2253 participants were screened.

Participant flow — Overall Study
MilestoneObeldesivirPlacebo
Started10051006
Completed977963
Not completed2843
Withdrew: Randomized but never treated1113
Withdrew: Withdrew consent715
Withdrew: Lost to follow-up513
Withdrew: Investigator's discretion31
Withdrew: Protocol violation20
Withdrew: Non-compliance with study drug01

Outcome measures

PrimaryTime to Coronavirus Disease 2019 (COVID-19) Symptom Alleviation by Day 29

The time to alleviation of targeted COVID-19 symptoms by Day 29 for participants with symptom alleviation, was calculated as symptom alleviation date/time minus first dose date/time. For participants who completed Day 29 of the study or discontinued from the study before Day 29 without symptom alleviation (censored) and without inter-current events, time was calculated as last date/time on which symptom alleviation was assessed minus the first dose date/time or Day 28, whichever occurred first. Symptom alleviation was defined as, all targeted symptoms scored moderate or severe at baseline were scored as mild/none and all targeted symptoms scored mild/none at baseline were scored as none, for at least 48 consecutive hours. Targeted symptoms included: stuffy or runny nose, sore throat, shortness of breath, cough, low energy or tiredness, muscle or body aches, headache, chills or shivering and feeling hot or feverish. Kaplan-Meier (KM) estimates were used in outcome measure analysis.

Time frame:
First dose date up to Day 29
Reported as:
Median · days
Time to Coronavirus Disease 2019 (COVID-19) Symptom Alleviation by Day 29
daysObeldesivirPlacebo
Time to Coronavirus Disease 2019 (COVID-19) Symptom Alleviation by Day 295.9 (5.4 to 6.1)6.0 (5.8 to 6.3)
Statistical analysis
  • Obeldesivir vs Placebo · Stratified Log-rank test · p = 0.0681 (P-value calculated from stratified Log-rank test with randomization stratification factor as the strata.) · Hazard ratio (hr): 1.099 · 95% CI 0.997 to 1.211Hazard ratio and two-sided 95% confidence interval (CI) for hazard ratio were estimated using the Cox regression with randomization stratification factor as a covariate.
PrimaryPercentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

TEAEs were defined as 1 or both of the following: * Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug. * Any AEs leading to premature discontinuation of study drug. Percentages were rounded off.

Time frame:
First dose date up to Day 5 plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
percentage of participantsObeldesivirPlacebo
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)5.45.7
PrimaryPercentage of Participants Experiencing Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days. Percentages were rounded off.

Time frame:
First dose date up to Day 5 plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Laboratory Abnormalities
percentage of participantsObeldesivirPlacebo
Any grade77.578.5
Grade 3 or 46.18.5
PrimaryPercentage of Participants Experiencing Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation

Percentages were rounded off.

Time frame:
First dose date up to Day 5 plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation
percentage of participantsObeldesivirPlacebo
SAEs0.20.4
AEs leading to study drug discontinuation0.10
SecondaryTime to COVID-19 Symptom Resolution by Day 29

COVID-19 symptom resolution was defined as all targeted symptoms scored as none for at least 48 consecutive hours. The first day of the 48 consecutive hours was considered the date of symptom resolution. The time to COVID-19 symptom resolution was the time (expressed as days) from the first dose date/time to the date/time of symptom resolution. KM estimates were used in the outcome measure analysis.

Time frame:
Day 1 up to 29
Reported as:
Median · days
Time to COVID-19 Symptom Resolution by Day 29
daysObeldesivirPlacebo
Time to COVID-19 Symptom Resolution by Day 299.2 (8.9 to 10.0)9.3 (8.9 to 10.1)
Statistical analysis
  • Obeldesivir vs Placebo · Stratified Log-Rank Test · p = 0.5558 · Hazard ratio (hr): 1.036 · 95% CI 0.935 to 1.147Hazard ratio and two-sided 95% CI for hazard ratio were estimated using the Cox regression with randomization stratification factor as a covariate.
SecondaryPercentage of Participants With Moderate Relapse of COVID-19 Symptoms by Day 29

COVID-19 moderate symptom relapse was defined as having at least 1 symptom being moderate or severe OR at least 2 mild symptoms OR a hospitalization for COVID-19 or death, observed on a day during COVID-19 symptom relapse. Percentages were rounded off.

Time frame:
Up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With Moderate Relapse of COVID-19 Symptoms by Day 29
percentage of participantsObeldesivirPlacebo
Percentage of Participants With Moderate Relapse of COVID-19 Symptoms by Day 298.3 (6.4 to 10.5)9.0 (7.1 to 11.3)
Statistical analysis
  • Obeldesivir vs Placebo · Fisher's exact test · p = 0.6469
SecondaryPercentage of Participants With COVID-19 Related Medically Attended Visits (MAVs) or All-cause Death by Day 29

Medically attended visits were defined as interactions with health care professionals other than study staff or designees including hospitalization; in-person emergency, urgent, or primary care visits; or any other in-person visit attended by the participant and a health care professional. The nature and cause of the visit were identified. KM estimates were used in the outcome measure analysis. Percentages were rounded off.

Time frame:
Up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With COVID-19 Related Medically Attended Visits (MAVs) or All-cause Death by Day 29
percentage of participantsObeldesivirPlacebo
Percentage of Participants With COVID-19 Related Medically Attended Visits (MAVs) or All-cause Death by Day 290.1 (0.0 to 0.3)0.2 (0.0 to 0.5)
Statistical analysis
  • Obeldesivir vs Placebo · Log-rank test · p = 0.5581 · Hazard ratio (hr): 0.495 · 95% CI 0.045 to 5.464Hazard ratio and two-sided 95% CI were estimated using the Cox regression.
SecondaryPercentage of Participants With COVID-19 Related Hospitalization or All-cause Death by Day 29

COVID-19-related hospitalization was defined as ≥ 24 hours of acute care for a reason related to COVID-19, in a hospital or similar acute care facility, including emergency rooms or temporary facilities instituted to address medical needs of those with COVID-19. This included specialized acute medical care units within an assisted living facility or nursing home. This did not include hospitalization for the purposes of public health and/or clinical trial execution. The date and duration (if there was 1 day difference between the start date and end date) of hospital admission, and primary reason for hospitalization (including if the hospitalization was related to COVID-19) was to be recorded. Percentages were rounded off.

Time frame:
Up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With COVID-19 Related Hospitalization or All-cause Death by Day 29
percentage of participantsObeldesivirPlacebo
Percentage of Participants With COVID-19 Related Hospitalization or All-cause Death by Day 2900
SecondaryChange From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nasal Swab Viral Load at Day 5
Time frame:
Day 5
Reported as:
Least squares mean · log10 copies/mL
Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nasal Swab Viral Load at Day 5
log10 copies/mLObeldesivirPlacebo
Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nasal Swab Viral Load at Day 5-2.69 ± 0.019-2.71 ± 0.020
Statistical analysis
  • Obeldesivir vs Placebo · MMRM · p = 0.4254 (p-value was from Mixed-effects model repeated measures (MMRM) with baseline viral load and randomization strata as covariates.) · Least squares mean: 0.02 · 95% CI -0.03 to 0.0895% CI was from MMRM with baseline viral load and randomization strata as covariates.
SecondaryTime to Antigen Negativity

Time to antigen negativity was defined (in days) as the number of days to the first date of 2 consecutive dates achieving a negative result. Antigen negativity was defined as 2 consecutive negative SARS-CoV-2 rapid antigen test (regardless if there was missing data in between), or negative test at last available sample for participants who completed or discontinued from the study after at least 1 positive antigen test.

Time frame:
Day 1 up to Day 29
Reported as:
Median · days
Time to Antigen Negativity
daysObeldesivirPlacebo
Time to Antigen Negativity5.0 (3.0 to 6.0)5.0 (4.0 to 6.0)
Statistical analysis
  • Obeldesivir vs Placebo · Stratified Log-rank test · p = 0.0015 (P-value calculated from stratified Log-rank test with randomization stratification factor as the strata.) · Hazard ratio (hr): 1.138 · 95% CI 1.032 to 1.256Hazard ratio and two-sided 95% CI for hazard ratio were estimated using the Cox regression with randomization stratification factor as a covariate.
SecondaryPercentage of Participants With Viral Antigen Rebound

Viral antigen rebound was defined as any positive SARS-CoV-2 rapid antigen test after antigen negativity. Percentages were rounded off.

Time frame:
Up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With Viral Antigen Rebound
percentage of participantsObeldesivirPlacebo
Percentage of Participants With Viral Antigen Rebound1.5 (0.8 to 2.6)1.7 (1.0 to 2.9)
Statistical analysis
  • Obeldesivir vs Placebo · Fisher's exact test · p = 0.6978P-value was from the Fisher's exact test.
SecondaryPlasma Concentrations of GS-441524 (Metabolite of Obeldesivir)
Time frame:
Day 1, 0.75 hour and 2 hours; Day 3, Predose and 0.75 hour; Day 5, Predose and 0.75 hour
Reported as:
Mean · ng/mL
Plasma Concentrations of GS-441524 (Metabolite of Obeldesivir)
ng/mLObeldesivir
Day 1 (0.75 h)2528.97 ± 5633.223
Day 1 (2 h)2390.68 ± 4763.877
Day 3 (Predose)1103.79 ± 6500.997
Day 3 (0.75 h)3339.59 ± 11353.578
Day 5 (Predose)2599.61 ± 29678.065
Day 5 (0.75 h)4595.37 ± 30772.089
SecondaryPharmacokinetic (PK) Parameter: AUCtau,Steady-State of GS-441524

AUCtau is defined as the area under the concentration versus time curve over the dosing interval at steady-state.

Time frame:
Day 5
Reported as:
Mean · h*ng/mL
Pharmacokinetic (PK) Parameter: AUCtau,Steady-State of GS-441524
h*ng/mLObeldesivir
Pharmacokinetic (PK) Parameter: AUCtau,Steady-State of GS-44152418000 ± 10200
SecondaryPK Parameter: Ctau of GS-441524

Ctau is defined as the observed drug concentration at the end of the dosing interval.

Time frame:
Day 1 and Day 5
Reported as:
Mean · ng/mL
PK Parameter: Ctau of GS-441524
ng/mLObeldesivir
Day 1772 ± 761
Day 5735 ± 919
SecondaryPK Parameter: Cmax of GS-441524

Cmax is defined as the maximum observed plasma concentration of drug.

Time frame:
Day 1 and Day 5
Reported as:
Mean · ng/mL
PK Parameter: Cmax of GS-441524
ng/mLObeldesivir
Day 12910 ± 1010
Day 52920 ± 1220
SecondaryPercentage of Participants With Relapse of COVID-19 Symptoms by Day 29

Symptom relapse means at least 2 consecutive diary entries (regardless of missing data in between) where there was any symptom (regardless of severity) OR a hospitalization for COVID-19 or a death after short symptom recovery. Percentages were rounded off.

Time frame:
Up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With Relapse of COVID-19 Symptoms by Day 29
percentage of participantsObeldesivirPlacebo
Percentage of Participants With Relapse of COVID-19 Symptoms by Day 2910.9 (8.8 to 13.4)12.0 (9.7 to 14.5)
Statistical analysis
  • Obeldesivir vs Placebo · Fisher's exact test · p = 0.5707P-value was from the Fisher's exact test.

Adverse events

Collected over Adverse Events and All-Cause Mortality: Up to 35 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Obeldesivir0/1,005 (0%)2/979 (0.2%)0/979 (0%)
Placebo0/1,006 (0%)4/976 (0.4%)0/976 (0%)
Most frequent serious events
Most frequent serious events
EventObeldesivirPlacebo
Transient ischaemic attackNervous system disorders0/9791/976
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/9791/976
Bipolar disorderPsychiatric disorders0/9791/976
HypertensionVascular disorders0/9791/976
Gastroenteritis bacterialInfections and infestations1/9790/976
Ectopic pregnancyPregnancy, puerperium and perinatal conditions1/9790/976

Baseline characteristics

The Safety Analysis Set included all participants, who were randomized into the study and have received at least 1 dose of study drug, except from one of the site which did not comply with study rules.

Age, Categorical
Age, Categorical(Participants)ObeldesivirPlaceboTotal
<=18 years191534
Between 18 and 65 years9609611921
>=65 years000
Age, Continuous
Age, Continuous(years)ObeldesivirPlaceboTotal
Mean42 ± 12.941 ± 12.341 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)ObeldesivirPlaceboTotal
Female5835721155
Male396404800
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ObeldesivirPlaceboTotal
Hispanic or Latino9189011819
Not Hispanic or Latino6175136
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ObeldesivirPlaceboTotal
American Indian or Alaska Native033
Asian212142
Native Hawaiian or Other Pacific Islander000
Black or African American106101207
White8508481698
More than one race134
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(Participants)ObeldesivirPlaceboTotal
United States9629621924
Japan171431
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load(log10 copies/mL)ObeldesivirPlaceboTotal
Mean5.08 ± 1.4165.09 ± 1.4795.09 ± 1.448
08

Study locations

113 sites
  • EmVenio Research
    Alabaster, Alabama 35007, United States
  • Institute for Liver Health dba Arizona Clinical Trials
    Chandler, Arizona 85224, United States
  • The Institute for Liver Health dba Arizona Liver Health
    Tucson, Arizona 85712, United States
  • Franco Felizarta, MD
    Bakersfield, California 93301, United States
  • Velocity Clinical Research, Banning (IP Delivery and Administering Location)
    Banning, California 92220, United States
  • Benchmark Research
    Colton, California 92324, United States
  • Ascada Research
    Fullerton, California 92835, United States
  • Velocity Clinical Research
    La Mesa, California 91942, United States
  • IMAX Clinical Trials, LLC
    La Palma, California 90623, United States
  • Om Research LLC
    Lancaster, California 93534, United States
  • L.A. Universal Research Center, INC.
    Los Angeles, California 90057, United States
  • Amicis Research Center
    Northridge, California 91324, United States
  • Valley Clinical Trials
    Northridge, California 91325, United States
  • Fomat Medical Research
    Oxnard, California 93030, United States
  • Paradigm Clinical Research
    Redding, California 96001, United States
  • Zuckerberg San Francisco General Hospital
    San Francisco, California 94110, United States
  • Clearview Medical Research, LLC
    Santa Clarita, California 91351, United States
  • EmVenio Research
    Santa Monica, California 90404, United States
  • Med Partners, Inc. dba Premiere Medical Center of Burbank, Inc.
    Toluca Lake, California 91602, United States
  • Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • Encore Medical Research of Boynton Beach LLC
    Boynton Beach, Florida 33436, United States
  • Palm Harbor Dermatology d/b/a TrueBlue Clinical Research
    Brandon, Florida 33511, United States
  • Innovative Research of West Florida, Inc
    Clearwater, Florida 33756, United States
  • Prestige Clinical Research Center Inc
    Coral Gables, Florida 33134, United States
  • Beautiful Minds Clinical Research Center
    Cutler Bay, Florida 33157, United States
  • Vital Care Research
    Doral, Florida 33122, United States
  • UHC Research, LLC
    Doral, Florida 33126, United States
  • Proactive Clinical Research,LLC
    Fort Lauderdale, Florida 33308, United States
  • Evolution Clinical Trials, INC
    Hialeah Gardens, Florida 33016, United States
  • Qway Research LLC
    Hialeah, Florida 33010, United States
  • AGA Clinical Trials
    Hialeah, Florida 33012, United States
  • Research in Miami
    Hialeah, Florida 33013, United States
  • 3Sync, LLC
    Hialeah, Florida 33016, United States
  • Best Quality Research, Inc.
    Hialeah, Florida 33016, United States
  • Doral Medical Research
    Hialeah, Florida 33016, United States
  • Innovative Health
    Hollywood, Florida 33024, United States
  • Encore Medical Research, LLC
    Hollywood, Florida 33201, United States
  • Essential Clinical Research
    Miami Lakes, Florida 33014, United States
  • Palm Springs Community Health Center
    Miami Lakes, Florida 33014, United States
  • Angels Clinical Research Institute
    Miami Lakes, Florida 33016, United States
  • Quality Research of South Florida
    Miami Lakes, Florida 33016, United States
  • Advance Clinical Research Group
    Miami, Florida 33122, United States
  • Med-Care Research, Corp
    Miami, Florida 33125, United States
  • Southern Clinical Research LLC
    Miami, Florida 33125, United States
  • LCC Medical Research Institute, LLC
    Miami, Florida 33126, United States
  • Universal Medical and Research Center, LLC.
    Miami, Florida 33126, United States
  • CCM Clinical Research Group, LLC
    Miami, Florida 33133, United States
  • Global Health Clinical Trials Corp
    Miami, Florida 33135, United States
  • Retreat Medical Research
    Miami, Florida 33135, United States
  • Verus Clinical Research, Corp
    Miami, Florida 33135, United States
  • Clinical Trial Services, Corp
    Miami, Florida 33144, United States
  • Continental Clinical Research
    Miami, Florida 33144, United States
  • Dynamic Medical Research, LLC
    Miami, Florida 33144, United States
  • Nuren Medical & Research Center
    Miami, Florida 33144, United States
  • Advanced Care and Clinical Trials, LLC
    Miami, Florida 33155, United States
  • Bioclinical Research Alliance Inc.
    Miami, Florida 33155, United States
  • Cordova Research Institute, Inc
    Miami, Florida 33155, United States
  • D&H National Research Centers, INC
    Miami, Florida 33155, United States
  • Florida International Medical Research
    Miami, Florida 33155, United States
  • Miami Clinical Research
    Miami, Florida 33155, United States
  • Allied Biomedical Research Institute
    Miami, Florida 33166, United States
  • Diverse Clinical Research, LLC
    Miami, Florida 33175, United States
  • P&S Research, LLC.
    Miami, Florida 33175, United States
  • ProLive Medical Research, Corp
    Miami, Florida 33175, United States
  • Entrust Clinical Research
    Miami, Florida 33176, United States
  • Links Clinical Trials LLC
    Miami, Florida 33176, United States
  • Reed Medical Research Corp
    Miami, Florida 33176, United States
  • MedBio Trials LLC
    Miami, Florida 33180, United States
  • Clinical Site Partners, LLC dba Flourish Research
    Miami, Florida 33186, United States
  • Phoenix Research Center, LLC
    Miami, Florida 33186, United States
  • Oceanic Research Group
    North Miami Beach, Florida 33169, United States
  • Castillo Torres, MD PA
    Palm Springs, Florida 33406, United States
  • Family Clinical Trials, LLC
    Pembroke Pines, Florida 33026, United States
  • USPA Advance Concept Medical Research Group, LLC
    South Miami, Florida 33143, United States
  • Precision Clinical Research
    Sunrise, Florida 33351, United States
  • Angels Clinical Research Institute
    Tampa, Florida 33614, United States
  • Precision Research Center
    Tampa, Florida 33614, United States
  • Santos Research Center, CORP
    Tampa, Florida 33615, United States
  • Encore Medical Reseach of Weston, LLC
    Weston, Florida 33331, United States
  • Clinical Site Partners, LLC dba Flourish Research
    Winter Park, Florida 32789, United States
  • EmVenio Research
    Atlanta, Georgia 30315, United States
  • Agile Clinical Research Trials, LLC
    Atlanta, Georgia 30328, United States
  • Covenant Pulmonary Critical Care Research Institute
    East Point, Georgia 30344, United States
  • Velocity Clinical Research
    Lafayette, Louisiana 70508, United States
  • Tulane University School of Medicine
    New Orleans, Louisiana 70112, United States
  • Prime Global Research Inc
    Bronx, New York 10456, United States
  • Shelby Clinical Research, LLC
    Denver, North Carolina 28037, United States
  • The Brody School of Medicine at East Carolina University
    Greenville, North Carolina 27834, United States
  • Carolina Research Center, Inc.
    Shelby, North Carolina 28150, United States
  • Frontier Clinical Research, LLC
    Smithfield, Pennsylvania 15478, United States
  • Clinovacare Medical Research Center
    West Columbia, South Carolina 29169, United States
  • St Hope Foundation, Inc.
    Bellaire, Texas 77401, United States
  • PanAmerican Clinical Research
    Brownsville, Texas 78520, United States
  • Premier Pulmonary Critical Care and Sleep Medicine
    Denison, Texas 75020, United States
  • EmVenio Research
    Fort Worth, Texas 26134, United States
  • HDH Research Inc.
    Houston, Texas 77022, United States
  • The Crofoot Research Center, INC.
    Houston, Texas 77098, United States
  • Milton Haber, MD
    Laredo, Texas 78041, United States
  • SMS Clinical Research, LLC
    Mesquite, Texas 75149, United States
  • Village Health Partners
    Plano, Texas 75024, United States

Showing the first 100 of 113 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Nov 2023, 9 months.

Results were first posted in Dec 2024, 1 year after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 9 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2023
First posted
Feb 8, 2023
StartActual
Feb 8, 2023
Primary completionActual
Nov 28, 2023
CompletionActual
Jan 23, 2024
Results first posted
Dec 24, 2024
Last update
Dec 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05715528
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Feb 8, 2023
Start date
Feb 8, 2023
Primary completion
Nov 28, 2023
Completion
Jan 23, 2024
Results posted
Dec 24, 2024
Last update
Dec 24, 2024

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obeldesivir

Start the discussion